A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer

St. Vincent's University Hospital, Dublin

St. James Hospital, Dublin

Department of Medical Oncology, Dublin

Institut Jules Bordet - Medical Oncology and Translational Research, Brussels

Sint-Augustinus GZA Ziekenhuizen, Wilrijk

Grand Hopital de Charleroi - Site Notre Dame, Charleroi

Universitatsklinikum Schleswig, Kiel

Carolina Oncology Specialists, PA, Hickory

Lakeland Regional Cancer Center, Lakeland

Gabrail Cancer Center, Canton

Karmanos Cancer Institute, Detroit

Klinikum Mutterhaus der Borromaeerinnen, Trier

Montana Cancer Institute Foundation c/o Montana Cancer Specialists, Missoula

Hämatologisch-onkologische Praxis, Augsburg

Kenmar Research Institute, Los Angeles

Frauenklinik des Universitätsklinikums Erlangen, Erlangen

Bay Area Cancer Research Group, Pleasant Hill

Institution of Russian Academy of Medical Sciences Russian Oncology Research Centre, Moscow

Scientific-Research Institute of Oncology named after Petrov, Saint Petersburg

Saint-Petersburg State Medical University named after Pavlov, Saint Petersburg

Tula Regional Dispensary, Tula

"State Healthcare institution Kursk Regional Oncology Dispensary of Kursk Region Healthcare committee GUZ KOOD", Kursk

Pyatigorsk Oncology Dispensary, Pyatigorsk

"State Healthcare Institution Samara Regional Clinical Oncology Dispensary", Samara

State Therapeutic and Prophylactic Institution Chelyabinsk Regional Clinical Oncology Dispensary, Chelyabinsk

FN Kralovske Vinohrady, Prague

Faculty Hospital Na Bulovce, Prague

Centrum Onkologii-Instytut im., Warsaw

Wojewodzki Szpital, Wroclaw

Nottingham University Hospital, Nottingham